Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Senzime AB is a Swedish medical device company specializing in neuromuscular monitoring systems used during anesthesia to prevent postoperative respiratory complications. The company's flagship TetraGraph system measures muscle function in real-time during surgery, targeting a market where inadequate neuromuscular blockade reversal affects approximately 40% of patients globally. With 63.6% revenue growth but deep operating losses (-212% margin), Senzime is in early commercialization phase, burning cash to establish market presence in the US and European hospital systems.
Senzime employs a razor-razorblades model: selling TetraGraph capital equipment ($15,000-25,000 per unit estimated) to hospitals, then generating recurring revenue from proprietary single-use TetraSens electrodes required for each surgical procedure. The company targets operating rooms performing procedures requiring neuromuscular blockade (approximately 50 million annually in US/Europe). Competitive advantage stems from acceleromyography technology providing objective quantitative measurements versus subjective clinical assessment, addressing patient safety concerns and potential liability reduction for hospitals. Gross margin of 34.4% reflects manufacturing scale-up phase; target margins likely 60-70% at maturity as consumables mix increases.
US hospital system adoption announcements and group purchasing organization (GPO) contract wins
Quarterly TetraGraph unit placements and installed base growth trajectory
TetraSens electrode utilization rates per installed system (indicating recurring revenue momentum)
FDA regulatory milestones and reimbursement code approvals that expand addressable market
Cash runway updates and financing announcements given negative free cash flow of -$0.1B
Regulatory pathway complexity as FDA and European MDR requirements evolve, potentially requiring additional clinical trials or delaying product approvals for next-generation devices
Reimbursement uncertainty as payers may not adequately compensate hospitals for neuromuscular monitoring, limiting adoption incentive despite clinical benefits
Clinical practice inertia as anesthesiologists accustomed to qualitative assessment methods resist workflow changes, requiring extensive education and training investments
Established competitors like Medtronic and GE Healthcare could leverage existing hospital relationships and broader product portfolios to bundle neuromuscular monitoring into anesthesia workstations
Technology leapfrog risk if alternative monitoring modalities (ultrasound-based, non-invasive optical methods) emerge with superior accuracy or ease-of-use
Pricing pressure as market matures and competitors enter, potentially compressing target 60-70% gross margins before reaching scale
Cash burn sustainability with -$0.1B operating cash flow requiring ongoing financing; at current burn rate, existing cash may support 12-18 months of operations (estimate based on 5.43x current ratio)
Equity dilution risk as company likely requires additional capital raises before reaching profitability, potentially diluting existing shareholders by 30-50% over next 24 months
Working capital strain if revenue growth accelerates faster than cash collection, particularly with hospital payment cycles extending 60-90 days
moderate - Hospital capital equipment budgets show cyclical sensitivity during recessions as elective surgery volumes decline and procurement committees defer non-critical purchases. However, patient safety focus and liability concerns provide some demand stability. Approximately 60% of target procedures are non-elective, providing revenue floor. Economic weakness extending hospital budget approval cycles from 6-9 months to 12-18 months would materially slow adoption trajectory.
Rising rates create dual headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting 8.1x price/sales multiple; (2) Hospital systems face higher borrowing costs for capital equipment purchases, potentially slowing adoption. With debt/equity of only 0.04, Senzime has minimal direct interest expense exposure, but future financing rounds would occur at higher cost of capital. Current 5.43x current ratio provides liquidity buffer but negative FCF requires ongoing capital access.
Minimal direct credit exposure as customers are primarily investment-grade hospital systems with stable payment histories. However, tightening credit conditions could pressure hospital capital budgets and extend payment terms. Company's ability to access growth capital markets is critical given -130% FCF yield; credit market stress would elevate refinancing risk and potentially force dilutive equity raises.
growth - Attracts speculative growth investors and medical device specialists willing to accept 3-5 year path to profitability in exchange for potential 5-10x return if US market penetration reaches 10-15% of addressable market. High revenue growth (63.6%) despite deep losses appeals to momentum traders, while 34.5% EPS growth (from negative base) indicates improving unit economics. Not suitable for value or income investors given negative earnings and no dividend. Requires high risk tolerance for binary outcomes around regulatory approvals and adoption inflection points.
high - Small-cap medical device stock ($0.1B market cap) with limited liquidity and binary clinical/regulatory catalysts creates significant volatility. Six-month return of -12.4% versus one-year return of 10.9% demonstrates choppy trading pattern typical of pre-revenue growth stories. Swedish listing adds currency risk for US investors. Expect 40-60% annual volatility with potential for 20-30% single-day moves on material news (GPO contracts, financing announcements, clinical study results).
